Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

1,017

Sector

Biotechnology & Medical Research

Calendar

12/02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	217.32 $	+1.06%	4,82,827
13/26/13	215.05 $	+3.01%	13,64,742
12/26/12	208.76 $	+2.84%	12,10,711
09/26/09	202.99 $	-2.76%	8,94,393
08/26/08	208.75 $	-2.12%	4,42,326

Delayed Quote Nasdaq, January 15, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

184.79EUR

Average target price

226.49EUR

Spread / Average Target

+22.57%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 15/01/2026 am IST			5-day change	1st Jan Change
217.32 ^USD	+1.06%		+3.84%	+1.91%

10/01	Ascendis Pharma plans $120 million share repurchase program in 2026	RE
09/01	Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating	MT

Capitalization	1.13TCr 1.32TCr 1.06TCr 982.75Cr 1.83TCr 1,19200Cr 1.98TCr 12TCr 4.78TCr 57TCr 4.95TCr 4.85TCr 2,09200Cr	P/E ratio 2025 *	-54.5x	P/E ratio 2026 *	46.2x
Enterprise value	1.12TCr 1.3TCr 1.04TCr 969.76Cr 1.81TCr 1,17600Cr 1.95TCr 12TCr 4.71TCr 56TCr 4.89TCr 4.79TCr 2,06400Cr	EV / Sales 2025 *	15.7x	EV / Sales 2026 *	8.37x
Free-Float	97.58%	Yield 2025 *	-	Yield 2026 *	-

10/01	Ascendis Pharma plans $120 million share repurchase program in 2026	RE
09/01	Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating	MT
09/01	Ascendis Pharma A/S - Special Call
09/01	Ascendis Pharma A/S Announces Topline Results from Week 52 of COACH Trial Evaluating Combination Therapy in Children with Achondroplasia	CI
08/01	RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk	MT
26/12	European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week	MT
24/12	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
22/12	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
18/12	European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading	MT
17/12	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
16/12	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
12/12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
09/12	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT

09/01	Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating	MT
08/01	RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk	MT
17/25/17	Raymond James Initiates Ascendis Pharma A/S at Strong Buy	MT
09/25/09	Ascendis Pharma Submits Marketing Authorization Application for TransCon CNP in Europe	MT
08/25/08	RBC Raises Price Target on Ascendis Pharma to $240 From $230, Keeps Outperform, Speculative Risk	MT

Ascendis Pharma A/S Share Price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Valuation: Ascendis Pharma A/S

Chart: Ascendis Pharma A/S

Latest news: Ascendis Pharma A/S

Last Transcript: Ascendis Pharma A/S

Analysts' recommendations: Ascendis Pharma A/S

Press Releases: Ascendis Pharma A/S

News in other languages: Ascendis Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Ascendis Pharma A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

10/01	Ascendis Pharma A/S : 44th Annual J.P. Morgan Healthcare Conference Presentation	PU
10/01	Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
09/01	Ascendis Pharma A/S : COACH Trial Topline Week 52 Data	PU
09/01	Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)	AQ
05/01	Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference	AQ

11/11	Agenda van bedrijfsresultaten voor de week van 10 tot 14 november 2025: Chinese technologie, CoreWeave, Alstom en Vallourec in aantocht
13/25/13	En direct des marchés : EssilorLuxottica brille encore, Alibaba flambe, Chevron taille dans ses effectifs
13/25/13	Insubmersibles
14/25/14	En direct des marchés : le TikTok de Musk, Lindt et Cucinelli publient, Amundi temporise en Italie
14/25/14	Trump essaie la carotte après le bâton

1 day	+1.06%
1 week	+3.84%
Current month	+1.91%
1 month	-1.41%
3 months	+4.27%
6 months	+24.21%
Current year	+1.91%

1 week	188.08	221.75
1 month	188.08	221.75
Current year	188.08	221.75
1 year	118.03	229.94
3 years	64.33	229.94
5 years	61.58	229.94
10 years	11.92	229.94

Manager	Title	Age	Since
Jan Mikkelsen CEO	Chief Executive Officer	67	01/12/2007
Scott Smith DFI	Director of Finance/CFO	53	08/08/2016
Stina Singel CTO	Chief Tech/Sci/R&D Officer	53	01/05/2020

Director	Title	Age	Since
Jan Mikkelsen BRD	Director/Board Member	67	01/12/2007
Albert Cha CHM	Chairman	54	28/05/2021
Lisa Bright BRD	Director/Board Member	59	01/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ASCENDIS PHARMA A/S	+1.06%	+3.84%	+62.13%	+88.92%	1.32TCr
LONZA GROUP AG	-0.46%	+3.79%	+2.50%	+13.83%	4.91TCr
IQVIA HOLDINGS INC.	-0.09%	+0.34%	+17.94%	+8.65%	4.11TCr
BEONE MEDICINES AG	-1.23%	+8.24%	+87.83%	+28.11%	3.88TCr
CELLTRION, INC.	-4.30%	-0.70%	+19.67%	+36.66%	3.27TCr
REVOLUTION MEDICINES, INC.	+1.06%	+51.81%	+184.75%	+302.86%	2.32TCr
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.08%	+6.48%	+26,107.15%	+4,371.14%	1.61TCr
MEDPACE HOLDINGS, INC.	+1.32%	+1.24%	+75.12%	+169.71%	1.71TCr
EUROFINS SCIENTIFIC SE	-1.53%	+4.65%	+46.91%	+11.70%	1.5TCr
ICON PUBLIC LIMITED COMPANY	+0.81%	-8.29%	-15.24%	-17.69%	1.4TCr
Average	+0.47%	+6.23%	+2,658.88%	+501.39%	2.61TCr
Weighted average by Cap.	-0.14%	+6.61%	+1,657.84%	+325.12%

	2025 *	2026 *
Net sales	72Cr 83Cr 67Cr 62Cr 115.58Cr 7.52TCr 124.65Cr 765.6Cr 301.19Cr 3.6TCr 312.23Cr 305.77Cr 13TCr	130.84Cr 152.36Cr 121.84Cr 113.36Cr 211.49Cr 14TCr 228.08Cr 1.4TCr 551.12Cr 6.6TCr 571.33Cr 559.5Cr 24TCr
Net income	-19Cr -22Cr -18Cr -16Cr -31Cr -2TCr -33Cr -203.42Cr -80Cr -957.81Cr -83Cr -81Cr -3.5TCr	24Cr 28Cr 23Cr 21Cr 40Cr 2.57TCr 43Cr 261.75Cr 102.97Cr 1.23TCr 106.75Cr 104.54Cr 4.51TCr
Net Debt	-15Cr -17Cr -14Cr -13Cr -24Cr -1.58TCr -26Cr -160.5Cr -63Cr -755.72Cr -65Cr -64Cr -2.76TCr	-39Cr -45Cr -36Cr -34Cr -63Cr -4.08TCr -68Cr -416.08Cr -163.69Cr -1.96TCr -169.69Cr -166.18Cr -7.17TCr